TNSN05174A1 - Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires - Google Patents
Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoiresInfo
- Publication number
- TNSN05174A1 TNSN05174A1 TNP2005000174A TNSN05174A TNSN05174A1 TN SN05174 A1 TNSN05174 A1 TN SN05174A1 TN P2005000174 A TNP2005000174 A TN P2005000174A TN SN05174 A TNSN05174 A TN SN05174A TN SN05174 A1 TNSN05174 A1 TN SN05174A1
- Authority
- TN
- Tunisia
- Prior art keywords
- treatment
- inflammatory diseases
- inhibitors
- benzamide derivatives
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
Abstract
La présente invention propose des inhibiteurs du récepteur P2X7, consistant en dérivés de benzamide de formule (I), Dans laquelle R1 et R2 sont tels que définis dans la revendication 1. R3 représente un groupe hétérocyclyle en C1 à C10, lié par un atome d'azote, de formule (II), dans laquelle R4 et R7 sont tels que définis dans la revendication 1. Les composés de la présente invention sont utiles dans le traitement d'affections à médiation par la IL-1, comprenant, à titre non limitatif, des maladies inflammatoires telles que l'arthrose et la polyarthrite rhumatoïde ; des allergies, l'asthme, la maladie pulmonaire obstructive chronique (COPD), le cancer, une reperfusion ou une ischémie dans un ictus ou une attaque cardiaque, des maladies auto-immunes et d'autres affections.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43750502P | 2002-12-31 | 2002-12-31 | |
PCT/IB2003/006254 WO2004058270A1 (fr) | 2002-12-31 | 2003-12-19 | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide utilises comme inhibiteurs de p2x7 pour le traitement de maladies inflammatoires |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN05174A1 true TNSN05174A1 (fr) | 2007-05-14 |
Family
ID=32682427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2005000174A TNSN05174A1 (fr) | 2002-12-31 | 2005-06-30 | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires |
Country Status (40)
Country | Link |
---|---|
US (4) | US6974812B2 (fr) |
EP (1) | EP1581232B1 (fr) |
JP (1) | JP4560411B2 (fr) |
KR (1) | KR100689138B1 (fr) |
CN (1) | CN1732006A (fr) |
AP (1) | AP1997A (fr) |
AR (1) | AR042673A1 (fr) |
AU (1) | AU2003285716B2 (fr) |
BR (1) | BR0317803A (fr) |
CA (1) | CA2512193C (fr) |
CL (1) | CL2003002765A1 (fr) |
CO (1) | CO5580749A2 (fr) |
CR (1) | CR7884A (fr) |
DO (1) | DOP2003000790A (fr) |
EA (1) | EA008591B1 (fr) |
EC (1) | ECSP055884A (fr) |
ES (1) | ES2464350T3 (fr) |
GE (1) | GEP20084304B (fr) |
GT (1) | GT200300297A (fr) |
HR (1) | HRP20050609A2 (fr) |
IL (2) | IL168513A (fr) |
IS (1) | IS7840A (fr) |
MA (1) | MA27575A1 (fr) |
MX (1) | MXPA05006749A (fr) |
MY (1) | MY141984A (fr) |
NI (1) | NI200500118A (fr) |
NL (1) | NL1025148C2 (fr) |
NO (1) | NO20053587L (fr) |
NZ (1) | NZ539913A (fr) |
OA (1) | OA12978A (fr) |
PA (1) | PA8591801A1 (fr) |
PE (1) | PE20040802A1 (fr) |
PL (1) | PL378251A1 (fr) |
RS (1) | RS20050490A (fr) |
TN (1) | TNSN05174A1 (fr) |
TW (1) | TWI288133B (fr) |
UA (1) | UA82346C2 (fr) |
UY (1) | UY28153A1 (fr) |
WO (1) | WO2004058270A1 (fr) |
ZA (1) | ZA200503912B (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
EP1837330B1 (fr) * | 2003-05-12 | 2012-10-24 | Pfizer Products Inc. | Inhibiteurs benzamidiques du recepteur P2X7 |
EP1626962B1 (fr) | 2003-05-12 | 2007-02-28 | Pfizer Products Inc. | Inhibiteurs benzamidiques du recepteur p2x7 |
MXPA06014022A (es) * | 2004-06-29 | 2007-02-08 | Pfizer Prod Inc | Prcedimientos para preparar inhibidores de p2x7. |
MXPA06015273A (es) * | 2004-06-29 | 2007-03-15 | Pfizer Prod Inc | Procedimiento para preparar derivados de 5-[4-(2-hidroxi -etil)-3, 5-dioxo-4, 5-dihidro-3h-[1, 2, 4]-triazin -2-il]-benzamida con actividad inhibidora de p2x7 mediante reaccion del derivado no sustituido en posicion 4 de la triazina con un oxirano en |
CA2572119A1 (fr) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Therapies combinatoires dans lesquelles sont utilises des inhibiteurs de benzamide du recepteur p2x<sb>7</sb> |
SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
WO2006083214A1 (fr) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Composition pharmaceutique comprenant un antagoniste du recepteur p2x7 et un inhibiteur de hmg-coa reductase |
WO2007025366A1 (fr) * | 2005-08-29 | 2007-03-08 | Irma Bernatchez-Lemaire | Utilisation de composes histogranine et du type histogranine comme inhibiteurs de la fonction du recepteur p2x7 et comme agents anti-arthritiques |
US20100184802A1 (en) * | 2006-03-16 | 2010-07-22 | Kelly Michael G | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof |
GB0622472D0 (en) * | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
EP2124562B1 (fr) * | 2007-03-09 | 2016-04-20 | Second Genome, Inc. | Composés de bicyclohétéroaryle utilisés comme modulateurs de p2x7 et leurs utilisations |
GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
BRPI0910034B1 (pt) | 2008-03-25 | 2022-02-08 | Affectis Pharmaceuticals Ag | Antagonistas do p2x7r e composições farmacêuticas que os compreendem |
EP2243772B1 (fr) | 2009-04-14 | 2012-01-18 | Affectis Pharmaceuticals AG | Nouveaux antagonistes P2X7R et leur utilisation |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
AU2011252351A1 (en) | 2010-05-14 | 2012-10-11 | Affectis Pharmaceuticals Ag | Novel methods for the preparation of P2X7R antagonists |
WO2012110190A1 (fr) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes p2x7r et leur utilisation |
JP2014513671A (ja) | 2011-02-22 | 2014-06-05 | アクテリオン ファーマシューティカルズ リミテッド | P2x7受容体アンタゴニストとしてのベンズアミド誘導体 |
WO2012163456A1 (fr) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes de p2x7r et leur utilisation |
WO2012163792A1 (fr) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes de p2x7r et leur utilisation |
AR087274A1 (es) | 2011-07-22 | 2014-03-12 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
EA023752B1 (ru) * | 2011-10-03 | 2016-07-29 | Ооо "Эн.Си.Фарм" | Фармацевтический состав для инъекций, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, противоишемической активностью (варианты) |
SG11201403933UA (en) | 2012-01-20 | 2014-08-28 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EA021231B1 (ru) * | 2012-02-29 | 2015-05-29 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, обладающий сосудосуживающим, антиконгестивным, противовоспалительным действием (варианты) |
EA020041B1 (ru) * | 2012-03-11 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, противоишемической активностью (варианты) |
EA021266B1 (ru) * | 2012-03-14 | 2015-05-29 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, обладающий сосудосуживающим, антиконгестивным, противовоспалительным действием (варианты) |
EA020538B1 (ru) * | 2012-03-20 | 2014-11-28 | Ооо "Эн.Си.Фарм" | Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты) |
EA020539B1 (ru) * | 2012-03-26 | 2014-11-28 | Ооо "Эн.Си.Фарм" | Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты) |
EA020521B1 (ru) * | 2012-03-26 | 2014-11-28 | Ооо "Эн.Си.Фарм" | Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты) |
EA201200393A1 (ru) * | 2012-03-30 | 2013-09-30 | Анастасия Геннадьевна ЧЕЛЯЕВА | Фармацевтический состав, обладающий противомикробным, бактериостатическим действием (варианты) |
EA201200446A1 (ru) * | 2012-04-06 | 2013-10-30 | Анастасия Геннадьевна ЧЕЛЯЕВА | Твердая лекарственная форма, обладающая отхаркивающим, местным обволакивающим и противовоспалительным действием (варианты) |
EA020401B1 (ru) * | 2012-07-09 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий натрий, кальций, магний, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020109B1 (ru) * | 2012-10-01 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020402B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий натрий, кальций, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020403B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий натрий, кальций, магний, железо и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020389B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий натрий, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020060B1 (ru) * | 2012-10-01 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020404B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий кальций, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020043B1 (ru) * | 2012-10-01 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020361B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий магний, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020129B1 (ru) * | 2012-10-01 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020388B1 (ru) * | 2012-10-01 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, содержащий натрий, кальций, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) |
EA020143B1 (ru) * | 2012-10-02 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020063B1 (ru) * | 2012-10-02 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020021B1 (ru) * | 2012-10-02 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020061B1 (ru) * | 2012-10-02 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020062B1 (ru) * | 2012-10-02 | 2014-08-29 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) |
EA020162B1 (ru) * | 2012-10-04 | 2014-09-30 | Ооо "Эн.Си.Фарм" | Твердая лекарственная форма, обладающая желчегонным действием (варианты) |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
CA2890886C (fr) | 2012-12-12 | 2020-10-27 | Actelion Pharmaceuticals Ltd | Derives d'indole carboxamide utilises en tant qu'antagonistes du recepteur p2x7 |
WO2014097140A1 (fr) | 2012-12-18 | 2014-06-26 | Actelion Pharmaceuticals Ltd | Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 |
EA024401B1 (ru) * | 2012-12-28 | 2016-09-30 | Ооо "Биотехсинтез" | Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты) |
EP2956457B1 (fr) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Dérivés d'amides hétérocycliques utilisés comme antagonistes du récepteur p2x7 |
JP6282016B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | P2x7受容体アンタゴニストとしての複素環アミド誘導体 |
EA201300372A1 (ru) * | 2013-04-17 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Антиоксидантный фармацевтический состав (варианты) |
WO2015099107A1 (fr) * | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | Dérivé cyclique à six chaînons contenant de l'azote et composition pharmaceutique le contenant |
PL3287443T3 (pl) | 2015-04-24 | 2022-02-21 | Shionogi & Co., Ltd | 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca |
MX2019004107A (es) | 2016-10-17 | 2019-08-05 | Shionogi & Co | Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene. |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (fr) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
AU542544B2 (en) | 1980-03-12 | 1985-02-28 | Nippon Kayaku Kabushiki Kaisha | Tetrahydrophthalimide derivatives |
EP0077938A3 (fr) | 1981-10-23 | 1983-08-24 | Mitsubishi Kasei Corporation | Tétrahydrophtalimides N-(3-substituées aminophényl) et compositions herbicides les contenant |
GR80558B (en) | 1983-10-08 | 1985-02-06 | Nippon Kayaku Kk | Derivative of pyrazole and use thereof as a herbicide |
US4766233A (en) | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
HU196892B (en) | 1984-06-12 | 1989-02-28 | Fmc Corp | Herbicides containing as active substance derivatives of 2-phenil-1,2,4-triasine-3,5-dion and process for production of these derivatives |
GB8602342D0 (en) * | 1986-01-30 | 1986-03-05 | Janssen Pharmaceutica Nv | 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones |
EP0333791A1 (fr) | 1987-09-23 | 1989-09-27 | Ciba-Geigy Ag | Composes heterocycliques |
US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US5128351A (en) | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
EP0491441A1 (fr) | 1990-12-17 | 1992-06-24 | Shell Internationale Researchmaatschappij B.V. | Dérivés d'isoquinolinefongicides |
JP3089621B2 (ja) | 1990-12-17 | 2000-09-18 | 日産化学工業株式会社 | ウラシル誘導体 |
US5462938A (en) * | 1990-12-21 | 1995-10-31 | Annus; Gary D. | Arthropodicidal oxadiazinyl, thiadiazinyl and triazinyl carboxanilides |
GB9110679D0 (en) | 1991-05-17 | 1991-07-10 | Sandoz Ltd | Improvements in or relating to organic compounds |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
TW403741B (en) * | 1993-10-15 | 2000-09-01 | Takeda Chemical Industries Ltd | Triazine derivative, production and use thereof |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
DE4405614A1 (de) | 1994-02-22 | 1995-08-24 | Bayer Ag | Substituierte Triazolinone |
US5686061A (en) | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
GB9412603D0 (en) | 1994-06-23 | 1994-08-10 | Sandoz Ltd | Organic compounds |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
JPH0959236A (ja) * | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
JP3906935B2 (ja) * | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
CA2240946C (fr) | 1995-12-21 | 2002-09-10 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline et pyrazoline, inhibiteurs du facteur xa |
JP2000506538A (ja) | 1996-03-29 | 2000-05-30 | ジー.ディー.サール アンド カンパニー | メタ―置換フェニレン誘導体 |
CN1169791C (zh) * | 1996-09-06 | 2004-10-06 | 日本化药株式会社 | 新颖的乙酰胺衍生物和蛋白酶抑制剂 |
CZ225699A3 (cs) | 1996-12-23 | 2000-09-13 | Du Pont Pharmaceuticals Company | Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
DE19701287A1 (de) | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben |
EP1019375A1 (fr) | 1997-03-25 | 2000-07-19 | Astra Pharmaceuticals Limited | Nouveaux derives de pyridine et compositions pharmaceutiques les renfermant |
WO1998043973A1 (fr) | 1997-03-27 | 1998-10-08 | Novartis Ag | Produits intermediaires et procede pour preparer des derives de pyrimidine |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
US5861950A (en) | 1997-07-10 | 1999-01-19 | Particle Measuring Systems, Inc. | Particle detection system utilizing an inviscid flow-producing nozzle |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
SE9704272D0 (sv) | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
JPH11318492A (ja) | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | 蛍光発生性基質を含有する組成物 |
US6320078B1 (en) | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
NZ512339A (en) | 1998-12-16 | 2003-03-28 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
TR200102911T2 (tr) * | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
US6458952B1 (en) * | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
WO2000071512A1 (fr) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibiteurs du facteur xa |
SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
EP1088821A1 (fr) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Derives des sulfamides pharmaceutiquement actifs |
MXPA02005102A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Retro-anandamidas, ligandos de receptor de canabinoide de alta afinidad y estabilidad. |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10005284A1 (de) | 2000-02-07 | 2001-08-09 | Bayer Ag | Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen |
GB0006721D0 (en) | 2000-03-20 | 2000-05-10 | Mitchell Thomas A | Assessment methods and systems |
PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (fr) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7 |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
EP1626962B1 (fr) | 2003-05-12 | 2007-02-28 | Pfizer Products Inc. | Inhibiteurs benzamidiques du recepteur p2x7 |
MXPA06015273A (es) | 2004-06-29 | 2007-03-15 | Pfizer Prod Inc | Procedimiento para preparar derivados de 5-[4-(2-hidroxi -etil)-3, 5-dioxo-4, 5-dihidro-3h-[1, 2, 4]-triazin -2-il]-benzamida con actividad inhibidora de p2x7 mediante reaccion del derivado no sustituido en posicion 4 de la triazina con un oxirano en |
MXPA06014022A (es) | 2004-06-29 | 2007-02-08 | Pfizer Prod Inc | Prcedimientos para preparar inhibidores de p2x7. |
-
2003
- 2003-12-10 PA PA20038591801A patent/PA8591801A1/es unknown
- 2003-12-11 PE PE2003001267A patent/PE20040802A1/es not_active Application Discontinuation
- 2003-12-12 DO DO2003000790A patent/DOP2003000790A/es unknown
- 2003-12-19 CA CA2512193A patent/CA2512193C/fr not_active Expired - Lifetime
- 2003-12-19 EA EA200500777A patent/EA008591B1/ru not_active IP Right Cessation
- 2003-12-19 RS YUP-2005/0490A patent/RS20050490A/sr unknown
- 2003-12-19 PL PL378251A patent/PL378251A1/pl not_active Application Discontinuation
- 2003-12-19 ES ES03778700.9T patent/ES2464350T3/es not_active Expired - Lifetime
- 2003-12-19 MX MXPA05006749A patent/MXPA05006749A/es active IP Right Grant
- 2003-12-19 GE GEAP20038875A patent/GEP20084304B/en unknown
- 2003-12-19 CN CNA2003801080357A patent/CN1732006A/zh active Pending
- 2003-12-19 OA OA1200500193A patent/OA12978A/fr unknown
- 2003-12-19 BR BR0317803-0A patent/BR0317803A/pt not_active IP Right Cessation
- 2003-12-19 EP EP03778700.9A patent/EP1581232B1/fr not_active Expired - Lifetime
- 2003-12-19 JP JP2004563515A patent/JP4560411B2/ja not_active Expired - Lifetime
- 2003-12-19 KR KR1020057012272A patent/KR100689138B1/ko not_active IP Right Cessation
- 2003-12-19 UA UAA200506391A patent/UA82346C2/uk unknown
- 2003-12-19 AU AU2003285716A patent/AU2003285716B2/en not_active Ceased
- 2003-12-19 NZ NZ539913A patent/NZ539913A/en not_active IP Right Cessation
- 2003-12-19 AP AP2005003350A patent/AP1997A/xx active
- 2003-12-19 WO PCT/IB2003/006254 patent/WO2004058270A1/fr active Application Filing
- 2003-12-22 GT GT200300297A patent/GT200300297A/es unknown
- 2003-12-24 MY MYPI20034989A patent/MY141984A/en unknown
- 2003-12-26 CL CL200302765A patent/CL2003002765A1/es unknown
- 2003-12-29 UY UY28153A patent/UY28153A1/es unknown
- 2003-12-29 AR ARP030104854A patent/AR042673A1/es unknown
- 2003-12-30 NL NL1025148A patent/NL1025148C2/nl not_active IP Right Cessation
- 2003-12-30 US US10/748,340 patent/US6974812B2/en not_active Expired - Lifetime
- 2003-12-30 TW TW092137490A patent/TWI288133B/zh not_active IP Right Cessation
-
2005
- 2005-05-09 IS IS7840A patent/IS7840A/is unknown
- 2005-05-10 IL IL168513A patent/IL168513A/en not_active IP Right Cessation
- 2005-05-16 ZA ZA200503912A patent/ZA200503912B/en unknown
- 2005-06-21 EC EC2005005884A patent/ECSP055884A/es unknown
- 2005-06-23 CR CR7884A patent/CR7884A/es unknown
- 2005-06-24 CO CO05061938A patent/CO5580749A2/es not_active Application Discontinuation
- 2005-06-29 NI NI200500118A patent/NI200500118A/es unknown
- 2005-06-30 MA MA28367A patent/MA27575A1/fr unknown
- 2005-06-30 TN TNP2005000174A patent/TNSN05174A1/fr unknown
- 2005-06-30 HR HR20050609A patent/HRP20050609A2/hr not_active Application Discontinuation
- 2005-07-22 NO NO20053587A patent/NO20053587L/no not_active Application Discontinuation
- 2005-10-27 US US11/260,075 patent/US7176202B2/en not_active Expired - Lifetime
-
2007
- 2007-01-08 US US11/620,969 patent/US7407956B2/en not_active Expired - Lifetime
-
2008
- 2008-06-26 US US12/147,212 patent/US7671053B2/en not_active Expired - Lifetime
-
2011
- 2011-04-10 IL IL212241A patent/IL212241A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05174A1 (fr) | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
TNSN07248A1 (fr) | Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases | |
MA27725A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA27881A1 (fr) | Derives d'imidazole utilises comme antagonistes du recepteur du glutamate | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MA27009A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
MA30694B1 (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
MA28667B1 (fr) | Derives d'acide benzimidazolonecarboxylique | |
MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
JP2023085428A5 (fr) | ||
TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA27569A1 (fr) | Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases | |
TNSN07319A1 (fr) | Derives d'oxindole servant d'agonistes du recepteur 5ht4 | |
MA28147A1 (fr) | Derives de pyrazole a titre de medicaments pour le traitement des degenerescences neuronales aigues ou chroniques | |
MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
ATE414703T1 (de) | Isoxazolderivate als inverse gaba a alpha5 agonisten | |
ATE438632T1 (de) | Aryl-4-ethinylisoxazolderivate | |
ATE466858T1 (de) | 3-arylisoxazol-4-carbonylbenzofuranderivative |